Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

BPC-157

Body Protection Compound-157, PL-14736, Pentadecapeptide BPC 157

Quick Stats
Studies 196
Trials 1
Score 3
2001 pubmed

Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats.

Stancic-Rokotov. D D; Slobodnjak. Z Z; Aralica. J J; Aralica. G G; Perovic. D D; Staresinic. M M; Gjurasin. M M; Anic. T T; Zoricic. I I; Buljat. G G; Prkacin. I I; Sikiric. P P; Seiwerth. S S; Rucman. R R; Petek. M M; Turkovic. B B; Kokic. N N; Jagic. V V; Boban-Blagaic. A A

Key Findings

  • BPC‑157 given before and after an acid‑induced lung injury lessened the size of the lesions in rats.
  • Repeated dosing (pre‑treatment plus a later dose) was more effective than a single dose.
  • High‑dose BPC‑157 (10 µg/kg i.p.) showed the greatest reversal of severe lung damage, comparable to some anti‑ulcer drugs.

Practical Outcomes

  • For biohackers, the study hints that BPC‑157 could have protective effects beyond the gut, potentially aiding lung health after acute irritants. However, because the data are from rats and use intraperitoneal injection, there’s no clear, safe protocol for humans yet. Anyone interested should wait for human trials or consult a medical professional before trying BPC‑157 for lung protection.

Summary

In rats, the ulcer‑healing peptide BPC‑157 (and some common anti‑ulcer drugs) reduced damage to the lungs caused by a strong acid spill. The protection was strongest when the peptide was given both before the injury and again later, and higher doses worked best. These results suggest BPC‑157 might help protect lung tissue, but the work is still in animals and the exact human dose isn’t known.

Abstract

Anti-ulcer agents may likely attenuate lesions outside the gastrointestinal tract, since they had protected gastrectomized rats (a "direct cytoprotective effect"). Therefore, their therapeutic potential in lung/stomach lesions were shown. Rats received an intratracheal (i.t.) HCl instillation [1.5 ml/kg HCl (pH 1.75)] (lung lesion), and an intragastric (i.g.) instillation of 96% ethanol (gastric lesion; 1 ml/rat, 24 h after i.t. HCl instillation), then sacrificed 1 h after ethanol. Basically, in lung-injured rats, the subsequent ethanol-gastric lesion was markedly aggravated. This aggravation, however, in turn, did not affect the severity of the lung lesions in the further period, at least for 1 h of observation. Taking intratracheal HCl-instillation as time 0, a gastric pentadecapeptide, GEPPPGKPADDAGLV, M.W.1419, coded BPC 157 (10 microg, 10 ng, 10 pg), ranitidine (10 mg), atropine (10 mg), omeprazole (10 mg), were given [/kg, intraperitoneally (i.p.)] (i) once, only prophylactically [as a pre-treatment (at -1h)], or as a co-treatment [at 0)], or only therapeutically (at +18h or +24 h); (ii) repeatedly, combining prophylactic/therapeutic regimens [(-1 h)+(+24 h)] or [(0)+(+24 h)], or therapeutic/therapeutic regimens [(+18 h)+(+24 h)]. For all agents, combining their prophylactic and salutary regimens (at -1 h/+24 h, or at 0/+24 h) attenuated lung lesions; even if effect had been not seen already with a single application, it became prominent after repeated treatment. In single application studies, relative to controls, a co-treatment (except to omeprazole), a pre-treatment (at -1 h) (pentadecapeptide BPC 157 and atropine, but not ranitidine and omeprazole) regularly attenuated, while therapeutically, atropine (at +18 h), pentadecapeptide BPC 157 highest dose and omeprazole (at +24 h), reversed the otherwise more severe lung lesions.

Study Information

Provider

pubmed

Year

2001

DOI

10.1016/s0928-4257(01)00042-0